BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Pfizer  Limited  submitted  on  12  September  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  ECALTA,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 1 June 2006. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The  application  submitted  is  a  complete  dossier:  composed  of  administrative  information,  complete 
quality  data,  non-clinical  and  clinical  data  based  on  applicants’  own  tests  and  studies  and/or 
bibliographic literature substituting/supporting certain test(s) or study(ies). 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
Anidulafungin has been given a Marketing Authorisation in the United States of America on 17 
February 2006. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  
Co-Rapporteur:  Jens Ersbøll 
CHMP Peer reviewer: Karl Broich 
Frits Lekkerkerker/Pieter de Graeff 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 12 September 2006. 
The procedure started on 27 September 2006.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 6 December 
2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 13 
December 2006.   
During  the  meeting  on  22-24  January  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 25 January 2007. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
16 March 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 1 May 2007. 
During  the  CHMP  meeting  on  21-24  May  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 8 June 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding Issues to all CHMP members on 2 July 2007. 
During the meeting on 16-19 July 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  ECALTA  on  19  July  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 18 July 2007. 
The CHMP opinions were forwarded, in all official languages of the European Union, to the 
European Commission, which adopted the corresponding Decisions on 20 September 2007. 
1/1 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
